Department of Traditional Chinese Medicine, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan, Taiwan.
Department of Applied Cosmetology, National Tainan Junior College of Nursing, Tainan, Taiwan.
Cancer Med. 2019 May;8(5):2514-2523. doi: 10.1002/cam4.2025. Epub 2019 Apr 9.
Benign Prostate Hyperplasia (BPH) has been associated with prostate cancer prevalent among men after 50 years of age, however, it is unclear whether the antidiabetic drug, metformin, can reduce prostate cancer for men with BPH. The insurance claims data of men aged 50 years or older, with both type 2 diabetes mellitus (T2DM) and BPH diagnosed from 1997 to 2007 were analyzed. Individuals were followed up for at least 5 years. We identified 2906 and 2906 patients as the metformin cohort and nonmetformin cohort, respectively. The Cox method analysis showed that the metformin cohort had an adjusted hazard ratio (aHR) of 0.69 (95% confidence interval [CI] = 0.49-0.96, P = 0.0298) for prostate cancer, compared to the nonmetformin cohort after controlling for age, traditional Chinese medicine (TCM) use, prostate specific antigen, and Charlson comorbidity index. Patients using TCM for BPH (per 6 months) also had an aHR of 0.41 (95% CI = 0.24-0.69; P = 0.0009). In conclusion, both metformin medication and TCM use could be associated with reduced risk of prostate cancer for men with BPH and diabetes.
良性前列腺增生（BPH）与 50 岁以上男性中常见的前列腺癌有关，然而，尚不清楚抗糖尿病药物二甲双胍是否可以降低患有 BPH 的男性的前列腺癌风险。分析了 1997 年至 2007 年间年龄在 50 岁或以上、同时患有 2 型糖尿病（T2DM）和 BPH 的男性的保险索赔数据。对这些人进行了至少 5 年的随访。我们分别将 2906 名和 2906 名个体确定为二甲双胍组和非二甲双胍组。Cox 方法分析显示，在控制年龄、中药（TCM）使用、前列腺特异性抗原和 Charlson 合并症指数后，与非二甲双胍组相比，二甲双胍组的前列腺癌调整后的危险比（aHR）为 0.69（95%置信区间[CI] = 0.49-0.96，P = 0.0298）。对于使用 TCM 治疗 BPH（每 6 个月）的患者，aHR 也为 0.41（95%CI = 0.24-0.69；P = 0.0009）。总之，二甲双胍治疗和 TCM 治疗均与患有 BPH 和糖尿病的男性前列腺癌风险降低相关。
